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BaCKgRoUND aND aIMS: Stratified therapy has en-
tered clinical practice in primary biliary cholangitis (PBC), 
with routine use of second- line therapy in nonresponders to 
first- line therapy with ursodeoxycholic acid (UDCA). The 
mechanism for nonresponse to UDCA remains, however, 
unclear and we lack mechanistic serum markers. The UK- 
PBC study was established to explore the biological basis of 
UDCA nonresponse in PBC and identify markers to enhance 
treatment.
appRoaCH aND ReSUltS: Discovery serum proteom-
ics (Olink) with targeted multiplex validation were carried 
out in 526 subjects from the UK- PBC cohort and 97 healthy 
controls. In the discovery phase, untreated PBC patients 
(n  =  68) exhibited an inflammatory proteome that is typi-
cally reduced in scale, but not resolved, with UDCA therapy 
(n  =  416 treated patients). Nineteen proteins remained at a 
significant expression level (defined using stringent criteria) 
in UDCA- treated patients, six of them representing a tightly 
linked profile of chemokines (including CCL20, known to be 
released by biliary epithelial cells (BECs) undergoing senes-
cence in PBC). All showed significant differential expression 
between UDCA responders and nonresponders in both the 
discovery and validation cohorts. A linear discriminant analy-
sis, using serum levels of C- X- C motif chemokine ligand 11 
and C- C motif chemokine ligand 20 as markers of responder 
status, indicated a high level of discrimination with an AUC 
of 0.91 (CI, 0.83- 0.91).
CoNClUSIoNS: UDCA under- response in PBC is char-
acterized by elevation of serum chemokines potentially related 
to cellular senescence and was previously shown to be released 
by BECs in PBC, suggesting a potential role in the patho-
genesis of high- risk disease. These also have potential for de-
velopment as biomarkers for identification of high- risk disease, 
and their clinical utility as biomarkers should be evaluated 
further in prospective studies. (Hepatology 2021;0:1-15).
Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease with a significant inflammatory/immune component.(1) The con-
dition is characterized by damage to, and eventual 
destruction of, the small intrahepatic bile ducts. Duct 
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damage is accompanied by portal inflammation, and 
interface hepatitis is frequently observed in patients 
with more- aggressive disease.(1) The disease is thought 
to arise because of a complex interplay of the choles-
tatic and immune processes. Standard therapy in PBC 
now uses a stratified approach.(2) Cholestatic injury, 
with damage to the biliary epithelial cells (BECs) lin-
ing the small intrahepatic bile ducts and eventual duc-
topenia, are the hallmarks of PBC and are thought to 
be mediated, at least in part, by hydrophobic bile acids. 
BEC apoptosis and senescence can both be observed 
within the affected liver.(3,4) Immune response in 
PBC is characterized by the almost universal pres-
ence of autoantibody and - reactive T- cell responses.(5) 
Autoreactive B- and T- cell responses in PBC have 
been well characterized, with autoreactivity against the 
highly conserved mitochondrial self- antigen, pyruvate 
dehydrogenase, being almost universal in patients.(6,7) 
Localization of CD8+ T- cell responses directed at 
mitochondrial antigens around affected ducts,(8) and 
the particular enrichment observed in early stages of 
the disease, point to a key role for the autoreactive 
immune response in PBC pathogenesis and a poten-
tial inter- relationship with bile duct injury processes. 
Understanding the inter- relationship between choles-
tatic and immune elements of the disease will be key 
as we move forward in terms of disease therapy.
First- line therapy for all patients is with ursode-
oxycholic acid (UDCA),(9) with second- line agents, 
such as obeticholic acid (OCA) and bezafibrate, 
being introduced in patients showing an inadequate 
response to UDCA.(10,11) Despite the apparent role 
played by immune processes in PBC pathogenesis, 
both first- and second- line treatment approaches 
currently recommended for PBC principally target the 
cholestasis component of the disease. To date, immu-
notherapy trials have proved disappointing.(12- 14) At 
present, adequacy of response to UDCA, and thus the 
need for second- line therapy, is assessed using blood 
biochemical markers of ongoing liver injury, typi-
cally alkaline phosphatase (ALP) and bilirubin. The 
UK- PBC program was established to recruit a large 
cohort of fully characterized PBC patients in the UK 
in order to study disease mechanisms, with a partic-
ular focus on why an important subgroup of patients 
do not respond to UDCA. One of the primary aims 
was to develop better tools for early identification of 
this subgroup.
In this two- stage study, we explored the serum 
inflammatory/immune proteome in PBC and its 
relationship to UDCA treatment response and non-
response. There were three groups of participants: 
treatment- naïve, newly presenting patients; patients 
established on UDCA therapy, stratified into UDCA 
responders and nonresponders; and healthy, age- 
matched controls. Evaluating PBC from the begin-
ning of its development, we aimed to identify the 
roles of key analytes in the different cohorts, differ-
ences between the cohorts, and what this could mean 
for downstream therapies.
Participants and Methods
StUDy DeSIgN aND SUBJeCtS
The aim of the study was to explore the serum pro-
teome of untreated and UDCA- treated PBC patients 
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to inform our understanding of the biology of the dis-
ease. In the discovery phase of the study, the serum 
proteomic profiles of informative subject groups from 
the UK- PBC patient cohort were assessed. These 
groups were treatment- naïve PBC patients (i.e., newly 
presenting patients before commencement of UDCA 
therapy; n = 68), PBC patients treated for a minimum 
of 12 months with UDCA therapy at an optimal dose 
and stratified for UDCA response (n  =  416), and 
healthy community controls (n = 97). In the validation 
stage, putative UDCA- response chemokine markers 
identified in the discovery phase were validated in 
a second, fully independent cohort of PBC patients 
stratified for UDCA response status recruited from 
the Newcastle clinical cohort (n = 46).
PBC study participants in the discovery phase were 
all members of the UK- PBC Cohort (www.UK- PBC.
com). This cohort was established to undertake studies 
of treatment efficacy in PBC to understand, in particu-
lar, the biological basis of high- risk disease. The details 
of the UK- PBC patient cohort have been described in 
detail.(15- 21) This is a large, prospective, national, cross- 
sectional cohort of PBC patients with detailed clinical 
data collection. Within the cohort is a nested subco-
hort with additional biofluid sampling and banking to 
accompany the clinical data collection.(22) The current 
study used samples from this subcohort. The valida-
tion cohort were patients under clinical follow- up in 
Newcastle for PBC who were not participants in the 
UK- PBC nested cohort study. All diagnoses of PBC 
were made on the basis of the standard criteria used 
in clinical practice, namely the presence of at least two 
of the three key PBC characteristics of cholestatic 
liver biochemistry, positive serum antimitochondrial 
or PBC- specific antinuclear antibodies at a titer of >1 
in 40, and compatible or diagnostic features on liver 
biopsy.(2) Subjects were classified as being patients with 
cirrhosis if they had biopsy confirmation of cirrhosis, 
varices, ascites, or a FibroScan value >17.3 KPa.(23)
UDCa- treated pBC
These were steady- state PBC patients who had been 
taking UDCA at a therapeutic dose (13- 15 mg/kg/d) 
for >12 months. Clinical parameters, including serum 
biochemistry, were available both pretreatment and 
at the study point. This allowed all UDCA- treated 
patients to be assigned to responder and nonre-
sponder groups using the POISE (Phase 3 Study of 
Obeticholic Acid in Patients With Primary Biliary 
Cirrhosis) criteria (ALP <1.67 × upper limit of normal 
[ULN] and bilirubin <1  ×  ULN).(10) UK- PBC risk 
score 10- year predicted survival was also calculated for 
all UDCA- treated patients after therapy.(19) Patients 
taking fibrates and or OCA were not included in the 
current study.
treatment- Naïve pBC
These were newly presenting PBC patients sam-
pled before the commencement of UDCA or any 
other PBC- related therapy.
Healthy Controls
These were healthy community controls, matched 
at the group level for age and sex to the treatment- 
naïve PBC patients. This cohort was recruited by the 
NIHR Cambridge BioResource specifically for com-
parison with the UK- PBC Nested Cohort and was 
used in the discovery phase of the study.
MetHoDS
Blood was collected under the approval of the 
Human Tissue Authority by the UK- PBC tissue 
bioresource with written informed patient consent 
obtained in accordance with research and ethics com-
mittee approval (14/NW/1146). Serum samples, once 
collected, were stored at −80°C until assayed using 
the Olink proteomics platform (www.olink.com). 
Serum (4  µL) was analyzed for 368 analytes from 
four distinct and complementary panels, including 
Cardiovascular II & III, Inflammation and Oncology 
II (www.olink.com/downl oads). Overall, 356 of 368 
analytes passed a quality- control threshold of >25% 
detectability. Using Proximity Extension Assay tech-
nology, antibodies labeled with oligonucleotides were 
hybridized to sample antigens, generating a barcode. 
In turn, this was amplified by microfluidic qPCR with 
normalized protein expression (NPX) data generated 
by a delta delta cycle threshold calculation method.
For the validation study, we measured levels of 
informative chemokines identified in the discov-
ery stage as being associated with UDCA nonre-
sponse (C- X- C motif chemokine ligand 9 [CXCL9; 
monokine induced by gamma interferon], C- X- C 
motif chemokine ligand 10 [CXCL10; interferon 
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gamma- induced protein 10], C- X- C motif chemok-
ine ligand 11 [CXCL11; interferon- inducible T- cell 
alpha chemoattractant], C- X- C motif chemokine 
ligand 13 [CXCL13; B- cell- attracting chemokine 1], 
C- C motif chemokine ligand 19 [CCL19; mac-
rophage inflammatory protein- 3- beta], and C- C 
motif chemokine ligand 20 [CCL20; macrophage 
inflammatory protein- 3- alpha]) using the Meso Scale 
Discovery (MSD, Rockville, MD) electrochemilu-
minescence assay platform. Specifically, we created a 
custom multi- PLEX panel for detecting the above 
analytes using the U- PLEX Custom Biomarker 
format. In order to retain uniformity and validity, 
assays were performed exactly as per the manufac-
turer’s instructions. Briefly, each of the biotinylated 
capture antibodies were covalently linked to specific 
spots within each well through use of unique linkers. 
Following a quenching step, plates were ready for 
sample application. Sera were thawed on ice and clar-
ified by centrifugation at 18,000g for 10  minutes at 
4°C. Sera were diluted 1:1 with supplied diluent and 
25  µL per well added in duplicate. A standard ana-
lyte cocktail dose- calibration curve was prepared and 
25 µL per well added in duplicate. Plates were incu-
bated for 2  hours at room temperature with shaking 
(200  RPM). Following a wash step, SULFO- TAG 
conjugated detection antibody cocktail (50  µL) was 
added to all wells and plates incubated as before. 
After washing, read buffer was added (150  µL) and 
the plates were read on the MSD Sector Imager 
6000 instrument. Data were analyzed using MSD 
Discovery Workbench (v4.0). This software uses four- 
parameter logistic (FourPL) calibration curve fitting 
from which sample values were derived. Each analyte 
had a lower limit of detection below all the sample 
values so all samples were in range and measurable. 
All sample values for all analytes are given as pg/mL.
StatIStICal aNalySIS
In the discovery study, NPX data were analyzed 
in R statistical programming software (version 3.5; 
R Foundation for Statistical Computing, Vienna, 
Austria), and differential expression between patient 
cohorts (UDCA- treated PBC, treatment- naïve PBC, 
and healthy controls [age- matched[) was calculated 
using the limma package (version 3.36.2; R Foundation 
for Statistical Computing). This is displayed as log fold 
change versus −log10 P value (adjusted for multiple 
comparisons); all values were thresholded at P < 0.05 
and 1.5- fold change. P values were adjusted for mul-
tiple comparisons using the Benjamini- Hochberg post 
hoc method. Direct comparison of individual analyte 
NPX data was performed with an unpaired t test 
using Welch’s correction (GraphPad Prism software 
7.0; GraphPad Software Inc., La Jolla, CA). Multiple 
linear regression was performed on the NPX data for 
correlations with ALP and log- transformed UK- PBC 
10- year mortality/transplant risk score in the differ-
ent PBC cohorts, again using the limma package in 
R. P values were adjusted for multiple comparisons as 
before. Protein- protein interaction (PPI) was analyzed 
using the STRING platform and the Gene Ontology 
(GO) classification.(24) Chemokines identified as dis-
ease associated in the discovery phase were used as 
descriptors of UDCA responder status in linear dis-
criminant analysis to identify those chemokines that 
could be used to optimally discriminate between 
patient responder status. We used a step- wise for-
ward variable selection method that started by iden-
tifying the markers that separated the responders and 
nonresponders most accurately. The model was then 
extended by including further variables depending 
on Wilk’s lambda. Wilk’s lambda tests how well each 
marker contributes to the model’s ability to discrimi-
nate between groups. Each marker was tested by put-
ting it into the model and then taking it out again, 
generating a Wilks Λ statistic. The significance of the 
change in Λ was measured with an  F test. If the F 
value was greater than the  critical value for F with 
the sample sizes, then the marker was included in the 
model and the analysis repeated with the remaining 
cytokines.  Selected markers (all chemokines) were 
then incorporated into a linear discriminant analysis 
so that discriminant functions could be abstracted 
and used to reclassify the original data into responder 
and nonresponder. Error rate of classification was cal-
culated (the proportion of cases incorrectly assigned 
to responder and nonresponder groups). Because the 
data set had comparatively few cases, we used a boot-
strapping procedure to estimate the robustness of the 
final model. For this, we randomly selected 90% of the 
case data and undertook the discriminant analysis on 
the subset and reclassified cases within it to responder 
and nonresponder groups. We repeated this 500 times 
and calculated the proportion of cases correctly clas-
sified. Analyses were repeated with log- transformed 
data, because the data were skewed with a few patients 
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with elevated levels of either chemokine. There was an 
assumption that the data were multivariate normal-
ity in using linear discriminant analysis, so we used 
logistic regression to assess the validity of the variables 
in the final model as predictors of responder/nonre-
sponder status. After having identified the key dis-
criminators for responder and nonresponder, we used 
ROC plot analysis to assess the diagnostic potential of 
the classification because the discrimination threshold 
was varied. We calculated the AUC for the receiver 
operating characteristic (ROC) plot as a further mea-
sure of the discriminative power of the model. AUC 
is scaled between 0 and 1; at 0 all cases are incorrectly 
classified, whereas at 1 all cases are correctly classi-
fied. Values between 0.8 and 0.9 are considered excel-
lent. All analyses were undertaken in the R statistical 
programming language using the libraries KlaR and 
MASS.
Results
Characteristics of the study cohorts are out-
lined in Table 1A (discovery cohort) and Table 1B 
(confirmatory cohort). Of the 416 subjects in the 
UDCA- treated group in the discovery cohort, 406 
had full data allowing UDCA response status to be 
assessed (97.5%). Of these, 127 (31%) were nonre-
sponders using the POISE criteria. In the validation 
cohort, all the patients had response data and 41% 
were UDCA nonresponders. Liver function tests were 
all normal in healthy controls.
DISCoVeRy pRoteoMICS StUDy
Initially, we explored and compared the inflam-
matory proteome in treatment- naïve PBC patients, 
UDCA- treated patients, and healthy controls in the 
discovery study (Fig. 1A- D). A consistent PBC dis-
ease profile, in terms of the protein signature in serum, 
was noted when treatment- naïve PBC patients were 
compared to healthy controls. Proteins significantly 
overexpressed in PBC are detailed in Table 2. The 
inflammatory proteome in UDCA- treated patients 
was almost identical to treatment- naïve patients, with 
only a single protein with a different expression pat-
tern between UDCA- treated and treatment- naïve 
patients (epithelial cell adhesion molecule; EpCAM). 
taBle 1. Clinical Characteristics of the Study Cohorts for (a) the proteomics Discovery Stage and (B) the Chemokine 
Confirmatory Stage of the Study
UDCA- Treated PBC Treatment- Naïve PBC Healthy Controls
(n = 416) (n = 68) (n = 97)
(A)
Median age (years) 63 58 64
Female (%) 89 82 76
With cirrhosis, n (%) 28 (7) 1 (1.5) na
UDCA treatment (%) 100 0 na
ALP at 1 year (SD) 178.2 (121.5) 226.5 (193.1) 70.9 (22.2)
ALT at 1 year (SD) 37.6 (28.9) 53.1 (34.7) 19.7 (8.6)
Bilirubin at 1 year (SD) 11.4 (10) 11.1 (8.4) 11.2 (5.5)
UDCA Responder PBC UDCA Nonresponder
(n = 27) (n = 19)
(B)
Median age (years) 65 56
Female (%) 91 89
UDCA treatment (%) 100 100
ALP at 1 year (SD) 80.9 (6.7) 342.3 (22.1)
ALT at 1 year (SD) 24.3 (4.0) 81.7 (11.9)
Bilirubin at 1 year (SD) 6.6 (0.5) 15.6 (4.4)
Abbreviation: na, not applicable.
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The extent to which analytes were differentially reg-
ulated in a similar manner in both groups of PBC 
patients (Fig. 1D) would suggest that although UDCA 
treatment reduces expression levels of inflammatory 
proteins in PBC, it does not change the expression 
pattern or normalize expression.
We went on to explore the relationship between the 
PBC proteome and both ALP levels in UDCA- naïve 
and UDCA- treated patients (Fig. 2A,B; Supporting 
Table S1) and the UK- PBC Risk Score 10- year pre-
dicted risk of death or transplant (Fig. 2C; Supporting 
Table S2). Ninety- two analytes in the treatment- 
naïve cohort and 184 analytes in the UDCA- treated 
cohort showed a significant correlation with ALP lev-
els. This finding suggests that ALP levels are asso-
ciated with disease mechanistic markers in both the 
treatment- naïve and UDCA- treated states. Similarly, 
in the UDCA- treated patient cohort, the UK- PBC 
Risk Score 10- year risk correlated significantly with 
138 analytes, validating the score as a mechanistically 
relevant prognostic tool in PBC. A similar pattern of 
associations was also observed for the UK- PBC score 
5- and 15- year predicted mortality/transplant risk 
(data not shown).
Significant PPI was observed among the proteins 
significantly overexpressed in treatment- naïve patients 
compared to healthy controls (PPI enrichment P value, 
<10−16), suggesting a functional expression pattern. 
The greatest enrichment was observed for cytokine- 
mediated signalling pathways, inflammatory response, 
and leucocyte chemotaxis GO terms (Table 3A). 
Comparison of UDCA- treated PBC patients and 
healthy controls demonstrated 19 proteins that 
remained significantly elevated despite UDCA ther-
apy (Supporting Fig. S1), with significant pathway 
enrichment particularly around chemotaxis where six 
inter- related chemokines were significantly elevated 
despite UDCA treatment (CCL19, CCL20, CXCL9, 
CXCL10, CXCL11, and CXCL13; Table 3B). All six 
chemokines showed significantly higher expression 
FIg. 1. Differential expression of serum proteins between UDCA- treated PBC, treatment- naïve PBC, and healthy control groups. (A) 
UDCA Tx (treated; n = 416) versus HC (n = 97), (B) naïve Tx (n = 68) versus HC, and (C) UDCA Tx versus naïve Tx. (D) Venn diagram 
summary of comparison between different cohorts. All analytes were thresholded for P < 0.05 and 1.5- fold change and are presented on 
a log scale. Red dots are significantly changed analytes >1.5- fold change (FC). P values were adjusted for multiple comparisons according 
to the Benjamini- Hochberg method. Abbreviations: HC, healthy controls; Tx, treatment.
A UDCA Tx vs HC B Naïve Tx vs HC
C UDCA Tx vs Naïve Tx D
Naïve Tx vs HC
UDCA Tx vs Naïve Tx
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taBle 2. proteins Showing Significant Differential expression Between Study groups in the Discovery proteomics Stage of the 
Study
Naïve Tx vs. HC UDCA Tx vs. Naïve Tx
Protein Analyte Log Fold Change Protein Analyte Log Fold Change




































Abbreviations: 5′- NT, 5′- nucleotidase; ACE2, angiotensin- converting enzyme 2; AP- N, aminopeptidase N; AZU1, azurocidin 1; CA5A, 
carbonic anhydrase 5A; CCL3, C- C motif chemokine ligand 3; CDCP1, CUB domain- containing protein 1; CXCL6, C- X- C motif 
chemokine ligand 6; DECR1, 2,4- dienoyl- CoA reductase; EN- RAGE, extracellular newly identified receptor for advanced glycation 
end products binding protein; GDF- 15, growth/differentiation factor- 15; HAOX1, hydroxyacid oxidase 1; IL- 1ra, interleukin- 1 receptor 
antagonist; IL- 4RA, Interleukin 4 receptor alpha; IL- 18R1, interleukin- 18 receptor 1; MetAP2, methionyl aminopeptidase 2; NEMO, 
NF- kappa- B essential modulator; SCAMP3, secretory carrier- associated membrane protein 3; TNFRSF4, TNF receptor superfam-
ily member 4; TNFRSF6B, TNF receptor superfamily member 6b; TNFRSF9, TNF receptor superfamily member 9; Tx, treatment; 
TXLNA, taxilin alpha; VIM, vimentin; XCL1, X- C motif chemokine ligand 1.
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levels in UDCA nonresponders using the POISE cri-
teria than responders (Fig. 3). Significant elevation of 
all six chemokines was still observed when this anal-
ysis was restricted to patients without cirrhosis. This 
is important given previous reports that cirrhosis per 
se can elevate related chemokine levels (Supporting 
Table S3). No proteins were significantly elevated in 
UDCA responders compared to nonresponders.
Correlations were significantly stronger for the 
six chemokines with ALP than with UK- PBC risk 
score (Supporting Tables S1 and S2). Exploration of 
the components of the UK- PBC risk score showed, 
in addition to the strong association with ALP lev-
els described above, strong associations with alanine 
aminotransferase (ALT) levels (Supporting Table S3). 
In contrast, only limited relationships to bilirubin, 
albumin, and platelet count were observed.
ValIDatIoN CHeMoKINe StUDy
We next studied the panel of six chemokines iden-
tified in the discovery phase of the study as being 
associated with UDCA nonresponse in a second 
PBC patient cohort stratified for UDCA response 
and nonresponse using a multiplex assay system. All 
six chemokines again had significantly higher lev-
els in UDCA nonresponders compared to respond-
ers (Supporting Fig. S2), confirming the original 
FIg. 2. Correlation of the PBC proteome with (A) ALP in UDCA- naïve patients, (B) ALP in UDCA- treated patients, and (C) log- 
transformed UK- PBC 10- year mortality/transplant risk in UDCA- treated patients. Serum ALP significantly correlates with a high 
number of analytes in both treatment- naïve cohorts and UDCA- treated patients, and UK- PBC risk score 10- year mortality risk correlates 
with analytes in the UDCA- treated group. These findings support a link between these biochemical/clinical markers and the inflammatory 
process in the disease. P values were adjusted for multiple comparisons according to the Benjamini- Hochberg method. Abbreviation: 
adj.P.Val, adjusted P value.
A ALP in UDCA-Naive Patients B ALP in UDCA-Treated Patients
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observation. Furthermore, the level of each of the 
six chemokines was, individually, highly predictive of 
UDCA nonresponse/response status (Fig. 4).
Finally, we went on to explore the capacity of 
chemokine elevation to act as a predictive mechanis-
tic marker for identification of UDCA nonresponse 
status using linear discriminant analysis in the con-
firmatory study cohort. Wilks’ lambda values for each 
of the chemokines, and the significance of their dis-
criminating power for separating responders and non-
responders, are shown in Table 4. Only four of the 
chemokines were good discriminators, and two of 
these, CXCL9 and CXCL13, did not lead to a signif-
icant increase in discrimination when added sequen-
tially to a model that included CCL20 and CXCL11. 
Reclassification of the original confirmatory study 
data set led to 40 patients (87% of the cases) being 
correctly classified, with 2 patients predicted to be 
nonresponders who were responders and 4 predicted 
to be responders who were not. A biplot of the non-
responder and responder levels of the two chemokines 
is shown in Fig. 5A. The classification status is based 
on use of discriminant functions that effectively find a 
plane in multivariate space that separates the groups. 
In the two groups, case values on this line below zero 
constitute membership of the nonresponder group, 
and values above zero predicted membership of the 
responder group. The bootstrapped discriminant anal-
yses, based on 500 repeat random samples of 90% of 
the data, gave a mean percentage correctly classified 
as 85.1% (SD = 2.3), suggesting that this is a robust 
classifier even when the sample size was reduced to 
90% of the data. Results of the analyses for the log- 
transformed data were very similar and are not pre-
sented further. A model for predicting the probability 
of a person being a responder or nonresponder on the 
basis of their serum levels of CXCL11 and CCL20 
can be accessed at https://natur aland envir onmen 
talsc ience.shiny apps.io/PBC_respo nder/. The AUC 
derived from the ROC plot analysis for the optimal 
predictive model was 0.91 (CI, 0.83- 0.99), indicat-
ing discriminatory power of these two chemokines to 
differentiate between responders and nonresponders 
(Fig. 5B).
taBle 3. Functional enrichments in the (a) treatment- Naïve pBC protein Network and (B) the UDCa- treated protein 
Network in the Discovery proteomics Stage of the Study
GO Term Description False Discovery Rate
(A)
0019221 Cytokine- mediated signaling pathway 3.6 × 10−22
0006954 Inflammatory response 7.9 × 10−20
0030595 Leucocyte chemotaxis 9.1 × 10−18
0006952 Defense response 4.2 × 10−17
0006955 Immune response 1.9 × 10−16
0051707 Response to other organism 4.0 × 10−16
0050921 Positive regulation of chemotaxis 6.8 × 10−16
0032496 Response to lps 2.2 × 10−15
0070098 Chemokine- mediated signaling pathway 8.4 × 10−15
0002687 Regulation of signaling receptor activity 1.5 × 10−14
(B)
0050900 Leucocyte migration 3.4 × 10−9
0048247 Lymphocyte chemotaxis 3.4 × 10−9
0031640 Killing of other organism 3.4 × 10−9
0006954 Inflammatory response 3.4 × 10−9
0030595 Leucocyte chemotaxis 6.2 × 10−9
0019730 Antimicrobial humoral response 9.1 × × 10−9
0070098 Chemokine- mediated signaling pathway 1.4 × 10−8
0019221 Cytokine- mediated signaling pathway 1.6 × 10−8
0002687 Positive regulation of leucocyte migration 1.6 × 10−7
0002690 Positive regulation of leucocyte chemotaxis 1.3 × 10−6
Data are shown for the 10 GO biological processes showing the greatest enrichment for each.
Abbreviation: lps, lipopolysaccharide.
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Discussion
In this study, we used two independent cohorts of 
phenotyped PBC patients, including treatment- naïve 
and UDCA- treated patients stratified by their therapy 
response status, to characterize the serum proteome 
in the disease. Our aim was to explore the biologi-
cal basis of nonresponse to UDCA in order to bet-
ter understand how to identify and treat higher- risk, 
therapy nonresponding patients. The findings begin to 
shed light on the mechanisms underpinning incom-
plete response to UDCA in PBC.
Our first observation was that, unsurprisingly, 
treatment- naïve PBC patients show elevation of a 
series of inflammatory protein markers in their serum 
when compared to healthy community controls. This 
supports the idea that there is a significant inflam-
matory/immune component to PBC pathogenesis. 
Elevations of these proteins correlate with both ALP 
levels, pre- UDCA and post- UDCA therapy, and with 
the UK- PBC risk score predicted 10- year mortality 
post- UDCA therapy.(19) To date, approval of second- 
line therapy in PBC has been on the basis of signifi-
cant improvement in the biochemical marker, ALP.(1) 
Although ALP is predictive of disease risk in clinical 
practice,(25) it is a surrogate marker at best and the 
lack of an apparent mechanistic link to the disease has 
weakened its value in the eyes of regulatory bodies. 
FIg. 3. Up- regulated chemokines in serum of UDCA nonresponders in the discovery proteomics study. Response criterion used was 
Paris 1 (although the effect was the same for the example chemokine, CCL20, regardless of the response criterion applied; Supporting 
Fig. S1). All analytes were assayed by the Olink platform and generated NPX. P values were calculated using an unpaired t test with 
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Our observation of a clear correlation between compo-
nents of the PBC proteome and levels of serum ALP 
(as well as with the composite UK- PBC risk score(19)) 
supports a direct link between ALP and underpinning 
immune and inflammatory processes and gives addi-
tional confidence in its use as a surrogate marker in 
clinical trials.
Comparison of the proteome in treatment- naïve 
and UDCA- treated patients in the discovery phase 
identified only a single protein (EpCAM) that was 
normalized by UDCA treatment. The other compo-
nents of the PBC proteome were reduced in expres-
sion level, but remained present at significantly 
elevated levels after UDCA therapy. This finding 
FIg. 4. Predictive value of serum chemokine levels for UDCA response status in the confirmatory study. All six chemokines identified in 
the discovery study as remaining elevated in PBC patients despite UDCA therapy, with significantly higher levels in UDCA nonresponders 
than responders, were also highly predictive of UDCA response status in the confirmatory study using an independent study cohort. 
(A) CCL20, (B) CXCL9, (C) CXCL10, (D) CCL19, (E) CXCL11, (F) CXCL13.
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taBle 4. Wilks’ lambda and Discrimination Between Responder and Nonresponder Status for Chemokines in the Confirmatory 
Chemokine Study
Chemokine Wilks’ Lambda F Statistic P Value F Difference P Difference
CCL20 0.689 19.85 5.68E- 0.5 19.85 5.68E- 0.5
CXCL11 0.518 19.99 7.29E- 07 14.17 4.91E- 0.4
CXCL9 0.498 14.13 1.64E- 0.6 1.74 1.94E- 0.1
CXCL13 0.476 11.26 2.94E- 0.6 1.82 1.84E- 0.1
CXCL9 and CXCL13 were nonsignificant at P > 0.05 and were hence excluded from the final linear discriminant analysis model.
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suggests that UDCA treatment modifies, but typically 
does not resolve, disease- associated inflammatory pro-
cesses in PBC.
The normalization of elevated serum EpCAM lev-
els in PBC with UDCA is open for study. EpCAM 
is an adhesion molecule expressed in the liver both by 
a mature cholangiocyte and a precursor cell popula-
tion.(26,27) Serum EpCAM has also recently been iden-
tified as a serum risk marker in inflammatory bowel 
disease.(28) Our interpretation of the findings in relation 
to EpCAM in PBC is that it is acting as a blood bio-
marker of cholangiocyte injury/functional cholangiocyte 
stem cell proliferation. In this model, normalization with 
UDCA reflects reducing biliary injury and subsequent 
precursor cell proliferation. This finding sheds further 
light on the actions of UDCA in the setting of PBC.
A significant element of the untreated PBC pro-
teome, persisting even after UDCA, is a network of 
chemokines (CCL20, CCL19, CXCL9, CXCL10, 
CXCL11, and CXCL13). CXCL9, - 10, and - 13 have 
been shown to be elevated in PBC patients, and not 
normalized by UDCA therapy; our findings confirm 
these earlier observations.(29- 31) In particular, levels 
of the individual CXCL chemokines were strongly 
correlated in the current study (data not shown), 
probably reflecting a shared regulation in the form of 
IL- 27.(32) Interestingly, the recent international meta- 
analysis of the genetic basis of PBC has identified the 
IL- 27 pathway as a PBC susceptibility pathway.(33) 
Significant up- regulation of CXCL9, CXCL10, and 
CCL19 has also been described in a murine PBC 
model, with levels being reduced by IL- 22 therapy.(34) 
CCL20, the gene encoding which was also identified 
as a susceptibility locus in PBC in the recent meta- 
analysis,(33) is released by injured BECs in PBC.(35,36)
In our study, we demonstrate, and then confirm in 
a second population, that levels of the six chemokines 
are significantly higher in UDCA nonresponders than 
UDCA responders. This effect was not a reflection 
of surrogate effects of cirrhosis given that the same 
association with UDCA nonresponse was observed 
when the analysis was restricted to patients without 
cirrhosis. Elevation of two chemokines, CCL20 and 
CXCL11, was sufficient to identify high- risk patients 
with a high degree of accuracy. Elevation in serum 
CCL20 and CXCL11 in high- risk PBC may reflect 
the process of BEC senescence. We have previously 
demonstrated that senescent BECs directly release 
CCL20.(37) Furthermore, although not studied as 
yet in the liver, CXCL11 release by endothelial cells 
FIg. 5. Predictive value of the integrated predictive model incorporating CXCL11 and CCL20 derived using linear discriminant 
modeling. (A) Density plot showing log- transformed individual levels of CCL20 and CXCL11 in nonresponders and responders. Highest 
density occurs where the contours are closest together. Note that while the contour lines in both plots would overlap if superimposed 
on the same graph, the centers for each group are different, responders generally having lower levels of both CCL20 and CXCL11 than 
nonresponders. (B) ROC analysis. The integrated model outperforms any individual chemokine and is the optimal tool for further 
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undergoing senescence has been reported.(38) BEC 
senescence has been shown to be a key adverse event 
in PBC pathogenesis, linked to both UDCA nonre-
sponse and high risk of disease progression.(39) In a 
transcriptomic and immunohistochemical study of 
the baseline liver biopsies of patients who went on to 
be nonresponders to UDCA and show disease pro-
gression, duct injury, including senescence as denoted 
by p21 expression, was present at disease outset, with 
CCL20 transcription up- regulated.(39) In contrast, 
CCL20 transcription was not upregulated in liver 
biopsies of low- risk patients at presentation and BEC 
senescence was absent. CCL20 appears to play a key 
role in the epithelial targeting of C- C motif chemo-
kine receptor 6 expressing T helper 17 and IL- 17- 
producing CD8+ T cells, strongly implicated in the 
immune pathogenesis of PBC.(40) Therefore, there 
appears to be an important, bidirectional crosstalk 
between immune cells and senescent BECs, with 
CCL20 playing a key role.(41) Far from being passive 
targets of immune injury in PBC, the BECs (espe-
cially in the context of cholestasis- induced senescence) 
appear to be complicit in shaping and localizing the 
immune response that contributes to their injury. The 
apparent role of BECs in modifying and localizing 
T- cell reactivity may help to explain the importance 
of interface hepatitis as an adverse marker in high- 
risk, UDCA nonresponsive disease.(42)
The apparent ongoing chemokine response 
in UDCA- treated PBC raises the question as to 
whether directly targeting the chemokine network 
itself may be a treatment option. A single study, 
targeting CXCL10, has explored this approach.(14) 
This trial was negative, potentially because of the 
pleomorphic nature of the IL- 27- induced chemo-
kine response. If the chemokine response is indeed 
a consequence of BEC injury, driving the aug-
mented immune response resulting from senescence 
that drives inflammation, it may be more produc-
tive to target the upstream processes resulting in 
BEC senescence, such as BEC oxidative stress in 
the context of cholestasis, rather than individual 
chemokines. In this context, our observation that 
measurement of just CCL20 and CXCL11 is suffi-
cient to identify UDCA nonresponders with a high 
degree of accuracy (addition of the other chemok-
ines to a predictive model does not further improve 
accuracy) points to a potentially useful mechanistic 
biomarker for high- risk PBC.
Our study has important limitations, and further 
work is needed in three particular areas. The first is a 
need to study a larger number of informative UDCA 
nonresponders. The UK- PBC study cohort used in 
the study had 31% UDCA nonresponders. This figure 
is typical for the UK experience for UDCA nonre-
sponse, but does mean that less- informative respond-
ers formed the majority of the participants. The 
second is a need for longitudinal sampling to explore 
within persons the change with UDCA, rather than 
relying on the current cross- sectional data. Finally, it 
will be important to explore changes in our CCL20/
CXCL11 marker with licensed and emerging second- 
line therapies. Our replication of the chemokine asso-
ciation with UDCA nonresponse in a second cohort 
does suggest, however, that the key finding is robust. A 
further limitation relates to the proteomics approach 
used. We selected four complementary marker panels 
based on earlier understanding of the biology of PBC 
(details of the markers can be found at www.olink.
com/downl oads). Clearly, the study cannot provide 
data in relation to any marker not included in these 
panels. Finally, the predictive value of the chemokine 
markers demonstrated in our study is for surrogate 
markers of disease- associated risk rather than direct 
clinical endpoints. Interestingly, the association is 
strongest with ALP and ALT than it is with bilirubin, 
albumin, and platelet counts (as well as the UK- PBC 
risk score integrating all five parameters). One inter-
pretation of this would be that chemokine elevation 
relates more closely to current disease activity than it 
does to severity in terms of progression to cirrhosis.
In conclusion, we have demonstrated that PBC 
has a characteristic inflammatory proteome. This is 
only modified to a modest degree by standard therapy 
with UDCA with, in particular, a prominent ongo-
ing chemokine response even on a therapeutic dose. 
This suggests a mechanism for UDCA nonresponse, 
potentially invoking ongoing BEC stress/senescence 
despite UDCA therapy. CCL20 and CXCL11 should 
be evaluated as potential mechanistic disease bio-
markers in the context of clinical trials.
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